GRAN® (Filgrastim) is a human Colony-Stimulating Factor (G-CSF) that is produced by genetic recombination technology. Pegfilgrastim is a Pegylated form of GCSF (Analog Filgrastim ) manufactured by Amgen (U.S.) and Kyowa Hakko Kirin (Japan).
Rivaroxaban with the brand name Xarelto is an anticoagulant which is developed by Bayer/ Johnson & Johnson. It is commonly used for dissolving or preventing a type of blood clot that is called deep vein thrombosis (DVT) by blocking the activity of certain clotting substances in the blood.
Sitagliptin previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia is an oral Type 2 diabetes medication manufactured by Merck & Co. This new oral hypoglycemic (anti-diabetic) drug is the top-selling brand in its class. In 2007, an oral combination of sitagliptin and metformin was marketed in the US as Janumet.